Contact this trialFirst, we need to learn more about you.
Virus Therapy
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF +1 More for Respiratory Syncytial Virus
Recruiting1 awardPhase 3
Kansas City, Missouri
This trial will enroll up to 27,500 people to see if the study vaccine prevents RSV-mediated Lower Respiratory Tract Disease (LRTD) better than placebo in adults aged 60 years and above.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.